Radiolabeled TTX-MC138 is intended for the treatment of advanced solid tumours. Credit: Christoph Burgstedt/Shutterstock.com.

TransCode Therapeutics has dosed the first subject in a first-in-human Phase 0 clinical trial of radiolabeled TTX-MC138 to treat advanced solid tumours.

Carried out under an investigational new drug application, the exploratory study intends to enrol nearly 12 subjects.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The study aims to quantify the amount of TTX-MC138 delivered to metastatic lesions and assess the pharmacokinetics of the candidate.

The first subject dosed with a single microdose of radiolabeled TTX-MC138 followed by positron emission tomography-magnetic resonance imaging (PET-MRI) showed good tolerance to the dosage.

Data obtained from the subject is being analysed and monitored including results of PET-MRI.

It will be further used for determining the uptake of TTX-MC138 in subject with metastatic lesions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, data from the trial, including therapeutic dosing, timing, and potential safety, will be used for initiating Phase I trial planned to begin next year.

TransCode CEO and co-founder Michael Dudley said: “The capability to deliver nucleic-acid based therapeutics to cancer represents a major turning point in the field of RNA because it opens up the possibility of developing an entire new class of drugs against most previously undruggable genetic targets.

“Overcoming this challenge could constitute an unprecedented step in unlocking therapeutic access to a range of cancers and beyond.

“Demonstrating successful delivery to cancer using TransCode’s proprietary TTX delivery platform could also enable progress towards more personalised cancer therapy guided by genetic profiling.”

TransCode considers TTX-MC138’s potential in improving breast, colon, ovarian and pancreatic cancer, glioblastomas and others.

Preliminary efficacy of TTX-MC138 was demonstrated in spontaneous feline mammary carcinoma and when administered as monotherapy in murine model of pancreatic adenocarcinoma it showed complete responses.